SI
Sofinnova Investments Portfolio holdings
AUM
$1.63B
1-Year Est. Return
33.42%
1 Year Est. Return
+33.42%
AUM
$1.63B
AUM Growth
+$160M
(+11%)
Holding
67
Top Buys
| 1 | +$46.2M | |
| 2 | +$40.7M | |
| 3 | +$36.4M | |
| 4 |
United Therapeutics
UTHR
|
+$30.2M |
| 5 |
Glaukos
GKOS
|
+$25.5M |
Top Sells
| 1 | +$83M | |
| 2 | +$75.6M | |
| 3 | +$34.2M | |
| 4 |
IDEAYA Biosciences
IDYA
|
+$33.3M |
| 5 |
Insmed
INSM
|
+$30.2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Disc Medicine
IRON
$3.47B
| $896K | 0.05% |
13,553
+6,241
|
|
||
52
Bolt Biotherapeutics
BOLT
$10.4M
| $733K | 0.04% |
137,721
|
|
||
53
Acadia Pharmaceuticals
ACAD
$4.59B
| $572K | 0.03% |
+26,800
|
|
||
54
Establishment Labs
ESTA
$2.11B
| $442K | 0.02% |
10,787
-17,333
|
|
||
|
IMA
55
ImageneBio Inc
IMA
$72.7M
| $260K | 0.01% |
31,884
-1
|
|
||
56
Structure Therapeutics
GPCR
$4.07B
| – | – |
-34,353
|
|
||
57
iShares Biotechnology ETF
IBB
$8.49B
| – | – |
0
|
|
||
|
INZY
58
DELISTED
Inozyme Pharma
INZY
| – | – |
-4,280,308
|
|
||
59
iShares Russell 2000 ETF
IWM
$73.5B
| – | – |
0
|
|
||
60
Eli Lilly
LLY
$920B
| – | – |
-97,018
|
|
||
61
Liquidia Corp
LQDA
$2.9B
| – | – |
0
|
|
||
62
Replimune Group
REPL
$799M
| – | – |
-1,806,529
|
|
||
63
Summit Therapeutics
SMMT
$13.1B
| – | – |
0
|
|
||
64
Syndax Pharmaceuticals
SNDX
$1.77B
| – | – |
-1,524,440
|
|
||
65
State Street SPDR S&P Biotech ETF
XBI
$7.67B
| – | – |
0
|
|
||
|
YMAB
66
DELISTED
Y-mAbs Therapeutics
YMAB
| – | – |
-2,194,278
|
|
||
|
MTSR
67
DELISTED
Metsera Inc
MTSR
| – | – |
-36,191
|
|